Friedenthal Financial Purchases Shares of 6,915 Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Friedenthal Financial purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,915 shares of the specialty pharmaceutical company's stock, valued at approximately $858,000.

A number of other hedge funds have also recently added to or reduced their stakes in JAZZ. Fuller & Thaler Asset Management Inc. increased its position in Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after purchasing an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $59,668,000. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after acquiring an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp raised its position in Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock worth $62,659,000 after acquiring an additional 296,800 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded down $0.73 during trading on Friday, reaching $107.51. The company had a trading volume of 1,053,788 shares, compared to its average volume of 827,456. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a 50-day moving average price of $108.14 and a two-hundred day moving average price of $120.06. The stock has a market capitalization of $6.51 billion, a PE ratio of 14.33, a price-to-earnings-growth ratio of 4.64 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm's revenue was down .5% on a year-over-year basis. During the same period in the previous year, the business earned $2.68 EPS. As a group, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Royal Bank Of Canada cut their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. HC Wainwright increased their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $184.00.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 500 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $107.90, for a total transaction of $53,950.00. Following the completion of the transaction, the chief executive officer now owns 438,473 shares of the company's stock, valued at $47,311,236.70. This represents a 0.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Seamus Mulligan bought 100,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 3,000 shares of company stock valued at $355,925 over the last quarter. Insiders own 4.30% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.